Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Log inSign up
Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Blog
Job Board
Q3AS

© 2026 Aqora Quantum S.A.S.

TermsPrivacyLegal Notice

Briefings in Bioinformatics

Quantum computing applications in drug discovery

Jing Li, Leyi Wei, Henry H Y Tong, Quan Zou

Published May 1, 2026• 5 citations
Publisher

Abstract

In early drug discovery, virtual screening based on deep learning, virtual screening based on molecular docking, and molecular dynamics are three widely used computational strategies, but they always face a trade-off between throughput, search stability, and physical fidelity. This article discusses how quantum computing can be integrated into these processes under the constraints of Noisy Intermediate-Scale Quantum (NISQ). At present, the most realistic role of quantum computing is not the complete replacement of classical processes, but modular coprocessing for selected decision-sensitive subroutines. In the screening of deep learning, quantum modules are mainly inserted into selected components of the model. In predictive models, they are used to enhance representation learning or feature extraction. In generative models, they serve as priors or generators. In docking screening, quantum integration is suitable for specific substeps such as site recognition, pose search, and flexible docking. In molecular dynamics, representative examples include ground state ab initio molecular dynamics, annealer-based trajectory propagation, and excited state molecular dynamics, while most large-scale sampling is still done by classical methods. The actual problem in these scenarios is not whether the quantum module can be inserted, but whether it can provide repeatable gains related to decision-making under the constraints of actual running time and resources. Therefore, we emphasize strong classical baselines, reliable ranking and calibration, transparent resource reporting, and evaluation at downstream decision points as key criteria for assessing progress in the near term.

DOI
10.1093/bib/bbag274

Related papers

Quantum computing in drug discovery

Harshraj N. Gadbail, Rajendra M. Rewatkar, Nishant Rajendra Jumde +3 more

Early-stage decisions in the pharmaceutical development process carry outsized consequences for eventual clinical success, yet the computational tools underpinning these decisions remain fundamentally constrained. Computer-aided drug design (CADD) has transformed how researchers navigate chemical space and predict ligand–target interactions, but classical implementations rely on mechanical force-field approximations that fail to capture polarisation, charge transfer, and electron correlation effects central to molecular recognition and reactivity. Quantum-mechanical treatments that correctly describe these phenomena scale exponentially with system size on classical hardware, rendering them impractical for drug-relevant biomolecules. Quantum computing offers a physically motivated path beyond this scaling barrier: by exploiting superposition, entanglement, and interference, quantum algorithms can in principle simulate electronic structure with polynomial resource requirements for targeted problem classes. This article provides a theoretical review of how quantum computation integrates throughout the drug discovery pipeline, from target identification to lead optimisation. Its primary contribution is a pipeline-level mapping of quantum methods—including the Variational Quantum Eigensolver (VQE), quantum machine learning, and quantum-enhanced optimisation—to specific drug development stages. The review critically distinguishes near-term NISQ (Noisy Intermediate-Scale Quantum: current devices with 50–1,000 noisy qubits operating without full error correction) capabilities from fault-tolerant quantum computing (FTQC) requirements, quantifies current resource gaps through a worked CYP3A4 case study, and identifies algorithmic limitations (barren plateaus, ansatz expressibility, measurement overhead), hardware scalability, and error correction overhead as the principal barriers to practical deployment.

Frontiers in Drug Discovery•Sep 7, 2026•0 citations

Quantum computing for biotechnological innovation: transformative potential in biomedicine and drug discovery

Ji‐Yong Sung, Seung-min Park, Jae‐Ho Cheong

Quantum computing has emerged as a potential catalyst for addressing computational bottlenecks that increasingly constrain biotechnologies, including drug discovery, structural biology, and precision medicine. As biological datasets grow in scale and complexity, classical high-performance computing struggles to efficiently model molecular interactions and high-dimensional biological systems. Recent advances in hybrid quantum-classical algorithms and quantum-enhanced machine learning have enabled early proof-of-concept applications on noisy intermediate-scale quantum (NISQ) devices, offering new strategies for molecular simulation, pattern recognition, and optimization. In this opinion article, we critically assess where quantum computing may deliver realistic near-term value for biomedicine, emphasize hybrid workflows as the most viable path forward, and outline how quantum technologies could complement, not replace, existing computational paradigms as the field progresses toward fault-tolerant systems.

Trends in biotechnology•Mar 5, 2026•6 citations

Applications of Quantum Computing in Drug Development

Enibokun Theresa Orobator, Teckla Tifuh Njei, Ikechukwu Kanu

Drug development remains a complex, time-intensive, and costly process, with high failure rates in clinical trials. The advent of quantum computing presents promising opportunities to transform pharmaceutical research and development through enhanced molecular simulations and structure-based drug design. Quantum computing uses quantum mechanical phenomena like superposition and entanglement to process complex molecular interactions more efficiently than classical computers. The integration of quantum computing with machine learning algorithms has enabled more accurate predictions of drug-target interactions and improved virtual screening of compound libraries. Applications include structure-based drug design, molecular docking, lead optimization, and drug repurposing. Notable progress has been made through collaborations between pharmaceutical companies and quantum computing firms, demonstrating practical implementations in drug discovery workflows. However, several challenges persist, including hardware limitations, algorithmic maturity, skilled workforce gaps, and regulatory considerations. The combination of quantum computing with classical computing and machine learning approaches offers a hybrid framework that maximizes the strengths of each technology. As quantum computing technology advances, it is positioned to significantly impact pharmaceutical research and development, potentially reducing development timelines and improving success rates in drug discovery. This review explains the principles, current applications, integration, and limitations of quantum computing in drug development

Journal of Pharma Insights and Research.•Jun 5, 2025•5 citations

Overcoming the Computational Explosion of Drug Discovery with Quantum Computing

inquantio

A study published on the preprint repository arXiv comprehensively outlines empirical applications of quantum algorithms (such as VQE, QAOA) that can be executed on near-term noisy intermediate-scale quantum (NISQ) hardware to solve key challenges in molecular biology and drug discovery, such as protein folding and molecular docking. Through quantum simulations that overcome the limits of classical computing, it was demonstrated that by directly simulating the Hamiltonian of a chemical system, the 3D energy-minimized state of peptides or small molecule compounds can be accurately predicted with significantly fewer computing resources than before. It provides a practical roadmap for combining quantum machine learning (QML) and molecular biology to dramatically reduce massive computational costs and achieve overwhelming efficiency in the next-generation in silico drug discovery process. [Quantum Biology Society] Problems such as protein folding and molecular docking, which cause the biggest bottlenecks in the drug discovery process, become exponentially more complex as the amino acid sequence gets longer. The number of cases to explore explodes, making it difficult for classical computers to handle their NP-hard complexity. Recently, a groundbreaking demonstration framework aiming to introduce the latest quantum computing algorithms into the pharmaceutical and biotechnology fields to overcome these limitations has been presented, drawing attention from the related industry. The paper titled "Quantum computing for molecular biology," published on the preprint repository arXiv, comprehensively covers the application of practical quantum algorithms (e.g., VQE, QAOA) capable of solving drug discovery challenges that have hit the limits of classical computing, using noisy intermediate-scale quantum (NISQ) hardware. A research team including Alberto Baiardi and Markus Reiher from ETH Zurich in Switzerland, along with Matthias Christandl from the University of Copenhagen in Denmark, led this innovative convergent research. ■ Quantum Simulation: Overcoming the Limits of Classical Computing The research team demonstrated that by utilizing the characteristic of quantum computers to efficiently map and directly simulate the Hamiltonian of chemical systems, the complex 3D energy-minimized states of peptides or small molecule compounds can be accurately found with significantly fewer computing resources than before. This is because quantum computers can fundamentally bypass the "curse of dimensionality," where the computational amount expands exponentially, by naturally simulating the quantum mechanical properties of molecules. ■ A Roadmap for Next-Generation Drug Discovery This research goes beyond simply presenting algorithms; it provides a specific roadmap for next-generation in silico drug discovery processes by combining quantum machine learning (QML) and molecular biology. Through this, it has opened a path to achieve overwhelming efficiency by drastically reducing the massive computational costs and time required to screen drug candidates and optimize their most stable binding structures. This practical guide strongly suggests that quantum computing will become a core foundational technology bringing substantial innovation to the life sciences and pharmaceutical industries in the future. https://arxiv.org/abs/2212.12220

•Jul 13, 2026•0 citations

Quantum computing for near-term applications in generative chemistry and drug discovery

Alexey N. Pyrkov, Alex Aliper, Dmitry S. Bezrukov +5 more

In recent years, drug discovery and life sciences have been revolutionized with machine learning and artificial intelligence (AI) methods. Quantum computing is touted to be the next most significant leap in technology; one of the main early practical applications for quantum computing solutions is predicted to be in quantum chemistry simulations. Here, we review the near-term applications of quantum computing and their advantages for generative chemistry and highlight the challenges that can be addressed with noisy intermediate-scale quantum (NISQ) devices. We also discuss the possible integration of generative systems running on quantum computers into established generative AI platforms.

Drug Discovery Today•Jun 16, 2023•112 citations

Quantum Computing in Molecular Design and Drug Discovery: A Systematic Literature Review

Charnelle Razo, Belinda Mutunhu Ndlovu

This study examines how quantum computing (QC) is being applied to molecular design and drug discovery. This study aims to investigates how QC surpasses classical limitations, focusing on empirical performance in precision, accuracy, and optimisation tasks. Study design use PRISMA 2009 guidelines, 15 empirical studies (2020-2025) were included. Data were extracted on the drug-discovery stage, the algorithm used, evaluation metrics, benefits, and limitations. The findings show QC outperforms classical methods particularly through hybrid quantum–classical models. Thirteen studies reported superior gains, including AUC–ROC values of 0.80–0.95, +30% improvement in drug-likeness (QED), +6% increase in prediction accuracy, and up to 99% accuracy in drug–target interaction tasks. However, noisy intermediate-scale quantum (NISQ) hardware limitations and poor scalability limit real-world deployment, due to noise, and limited qubit counts. Consequently, current performance results are largely simulation-based rather than hardware-validated. In contrast to prior algorithm-centric reviews, this study provides a consolidated empirical synthesis and proposes a hybrid quantum–classical pipeline that maps high-performing algorithms across the drug discovery workflow under NISQ-era constraints. These findings inform pharmaceutical research and development by identifying realistic adoption pathways and the boundaries of current technological readiness.

Journal of Information Systems and Informatics•Feb 12, 2026•2 citations
In early drug discovery, virtual screening based on deep learning, virtual screening based on molecular docking, and molecular dynamics are three widely used computational strategies, but they always face a trade-off between throughput, search stability, and physical fidelity. This article discusses how quantum computing can be integrated into these processes under the constraints of Noisy Intermediate-Scale Quantum (NISQ). At present, the most realistic role of quantum computing is not the complete replacement of classical processes, but modular coprocessing for selected decision-sensitive subroutines. In the screening of deep learning, quantum modules are mainly inserted into selected components of the model. In predictive models, they are used to enhance representation learning or feature extraction. In generative models, they serve as priors or generators. In docking screening, quantum integration is suitable for specific substeps such as site recognition, pose search, and flexible docking. In molecular dynamics, representative examples include ground state ab initio molecular dynamics, annealer-based trajectory propagation, and excited state molecular dynamics, while most large-scale sampling is still done by classical methods. The actual problem in these scenarios is not whether the quantum module can be inserted, but whether it can provide repeatable gains related to decision-making under the constraints of actual running time and resources. Therefore, we emphasize strong classical baselines, reliable ranking and calibration, transparent resource reporting, and evaluation at downstream decision points as key criteria for assessing progress in the near term.
Early-stage decisions in the pharmaceutical development process carry outsized consequences for eventual clinical success, yet the computational tools underpinning these decisions remain fundamentally constrained. Computer-aided drug design (CADD) has transformed how researchers navigate chemical space and predict ligand–target interactions, but classical implementations rely on mechanical force-field approximations that fail to capture polarisation, charge transfer, and electron correlation effects central to molecular recognition and reactivity. Quantum-mechanical treatments that correctly describe these phenomena scale exponentially with system size on classical hardware, rendering them impractical for drug-relevant biomolecules. Quantum computing offers a physically motivated path beyond this scaling barrier: by exploiting superposition, entanglement, and interference, quantum algorithms can in principle simulate electronic structure with polynomial resource requirements for targeted problem classes. This article provides a theoretical review of how quantum computation integrates throughout the drug discovery pipeline, from target identification to lead optimisation. Its primary contribution is a pipeline-level mapping of quantum methods—including the Variational Quantum Eigensolver (VQE), quantum machine learning, and quantum-enhanced optimisation—to specific drug development stages. The review critically distinguishes near-term NISQ (Noisy Intermediate-Scale Quantum: current devices with 50–1,000 noisy qubits operating without full error correction) capabilities from fault-tolerant quantum computing (FTQC) requirements, quantifies current resource gaps through a worked CYP3A4 case study, and identifies algorithmic limitations (barren plateaus, ansatz expressibility, measurement overhead), hardware scalability, and error correction overhead as the principal barriers to practical deployment.
Quantum computing has emerged as a potential catalyst for addressing computational bottlenecks that increasingly constrain biotechnologies, including drug discovery, structural biology, and precision medicine. As biological datasets grow in scale and complexity, classical high-performance computing struggles to efficiently model molecular interactions and high-dimensional biological systems. Recent advances in hybrid quantum-classical algorithms and quantum-enhanced machine learning have enabled early proof-of-concept applications on noisy intermediate-scale quantum (NISQ) devices, offering new strategies for molecular simulation, pattern recognition, and optimization. In this opinion article, we critically assess where quantum computing may deliver realistic near-term value for biomedicine, emphasize hybrid workflows as the most viable path forward, and outline how quantum technologies could complement, not replace, existing computational paradigms as the field progresses toward fault-tolerant systems.
Drug development remains a complex, time-intensive, and costly process, with high failure rates in clinical trials. The advent of quantum computing presents promising opportunities to transform pharmaceutical research and development through enhanced molecular simulations and structure-based drug design. Quantum computing uses quantum mechanical phenomena like superposition and entanglement to process complex molecular interactions more efficiently than classical computers. The integration of quantum computing with machine learning algorithms has enabled more accurate predictions of drug-target interactions and improved virtual screening of compound libraries. Applications include structure-based drug design, molecular docking, lead optimization, and drug repurposing. Notable progress has been made through collaborations between pharmaceutical companies and quantum computing firms, demonstrating practical implementations in drug discovery workflows. However, several challenges persist, including hardware limitations, algorithmic maturity, skilled workforce gaps, and regulatory considerations. The combination of quantum computing with classical computing and machine learning approaches offers a hybrid framework that maximizes the strengths of each technology. As quantum computing technology advances, it is positioned to significantly impact pharmaceutical research and development, potentially reducing development timelines and improving success rates in drug discovery. This review explains the principles, current applications, integration, and limitations of quantum computing in drug development
A study published on the preprint repository arXiv comprehensively outlines empirical applications of quantum algorithms (such as VQE, QAOA) that can be executed on near-term noisy intermediate-scale quantum (NISQ) hardware to solve key challenges in molecular biology and drug discovery, such as protein folding and molecular docking. Through quantum simulations that overcome the limits of classical computing, it was demonstrated that by directly simulating the Hamiltonian of a chemical system, the 3D energy-minimized state of peptides or small molecule compounds can be accurately predicted with significantly fewer computing resources than before. It provides a practical roadmap for combining quantum machine learning (QML) and molecular biology to dramatically reduce massive computational costs and achieve overwhelming efficiency in the next-generation in silico drug discovery process. [Quantum Biology Society] Problems such as protein folding and molecular docking, which cause the biggest bottlenecks in the drug discovery process, become exponentially more complex as the amino acid sequence gets longer. The number of cases to explore explodes, making it difficult for classical computers to handle their NP-hard complexity. Recently, a groundbreaking demonstration framework aiming to introduce the latest quantum computing algorithms into the pharmaceutical and biotechnology fields to overcome these limitations has been presented, drawing attention from the related industry. The paper titled "Quantum computing for molecular biology," published on the preprint repository arXiv, comprehensively covers the application of practical quantum algorithms (e.g., VQE, QAOA) capable of solving drug discovery challenges that have hit the limits of classical computing, using noisy intermediate-scale quantum (NISQ) hardware. A research team including Alberto Baiardi and Markus Reiher from ETH Zurich in Switzerland, along with Matthias Christandl from the University of Copenhagen in Denmark, led this innovative convergent research. ■ Quantum Simulation: Overcoming the Limits of Classical Computing The research team demonstrated that by utilizing the characteristic of quantum computers to efficiently map and directly simulate the Hamiltonian of chemical systems, the complex 3D energy-minimized states of peptides or small molecule compounds can be accurately found with significantly fewer computing resources than before. This is because quantum computers can fundamentally bypass the "curse of dimensionality," where the computational amount expands exponentially, by naturally simulating the quantum mechanical properties of molecules. ■ A Roadmap for Next-Generation Drug Discovery This research goes beyond simply presenting algorithms; it provides a specific roadmap for next-generation in silico drug discovery processes by combining quantum machine learning (QML) and molecular biology. Through this, it has opened a path to achieve overwhelming efficiency by drastically reducing the massive computational costs and time required to screen drug candidates and optimize their most stable binding structures. This practical guide strongly suggests that quantum computing will become a core foundational technology bringing substantial innovation to the life sciences and pharmaceutical industries in the future. https://arxiv.org/abs/2212.12220
In recent years, drug discovery and life sciences have been revolutionized with machine learning and artificial intelligence (AI) methods. Quantum computing is touted to be the next most significant leap in technology; one of the main early practical applications for quantum computing solutions is predicted to be in quantum chemistry simulations. Here, we review the near-term applications of quantum computing and their advantages for generative chemistry and highlight the challenges that can be addressed with noisy intermediate-scale quantum (NISQ) devices. We also discuss the possible integration of generative systems running on quantum computers into established generative AI platforms.
This study examines how quantum computing (QC) is being applied to molecular design and drug discovery. This study aims to investigates how QC surpasses classical limitations, focusing on empirical performance in precision, accuracy, and optimisation tasks. Study design use PRISMA 2009 guidelines, 15 empirical studies (2020-2025) were included. Data were extracted on the drug-discovery stage, the algorithm used, evaluation metrics, benefits, and limitations. The findings show QC outperforms classical methods particularly through hybrid quantum–classical models. Thirteen studies reported superior gains, including AUC–ROC values of 0.80–0.95, +30% improvement in drug-likeness (QED), +6% increase in prediction accuracy, and up to 99% accuracy in drug–target interaction tasks. However, noisy intermediate-scale quantum (NISQ) hardware limitations and poor scalability limit real-world deployment, due to noise, and limited qubit counts. Consequently, current performance results are largely simulation-based rather than hardware-validated. In contrast to prior algorithm-centric reviews, this study provides a consolidated empirical synthesis and proposes a hybrid quantum–classical pipeline that maps high-performing algorithms across the drug discovery workflow under NISQ-era constraints. These findings inform pharmaceutical research and development by identifying realistic adoption pathways and the boundaries of current technological readiness.